Title |
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
|
---|---|
Published in |
BMC Cancer, October 2017
|
DOI | 10.1186/s12885-017-3684-8 |
Pubmed ID | |
Authors |
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka |
Abstract |
We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received nab-paclitaxel, 100 mg/m(2) i.v. on days 1, 8, and 15 every 4 weeks. The primary endpoint was the overall response rate. Secondary endpoints were the progression-free survival time, overall survival, and the toxicity profile. From July 2013 to July 2015, a total of 31 patients were enrolled. Fourteen patients received nab-paclitaxel as a second-line and 17 received it as an over third-line therapy. Each patient received a median of 5 treatment cycles (range, 1-11). The overall response rate was 19.3% (95% confidence interval, 9.1-36.2%) (complete response (n = 0), partial response (n = 6), stable disease (n = 17), and progressive disease (n = 8)). The median progression-free survival time was 4.5 months (95% confidence interval 3.5-6.3 months), median overall survival time was 15.7 months, and 1-year survival rate was 54.8%. Most common grade 3 or 4 non-hematological toxicities were elevated aspartate transaminase level (3.2%) and sensory neuropathy (9.6%). Neutropenia was the most common grade 3 or 4 adverse events (38.6%), and febrile neutropenia developed in 12.9% patients. No treatment-related deaths were observed in this study. Primary endpoint was met. Single agent nab-paclitaxel showed significant clinical efficacy and manageable toxicities for patients with chemorefractory advanced non-small cell lung cancer even if late line setting. UMIN000011696 . The date of registration was July 11th, 2013. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 29 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 17% |
Lecturer | 4 | 14% |
Student > Ph. D. Student | 4 | 14% |
Other | 2 | 7% |
Student > Doctoral Student | 1 | 3% |
Other | 1 | 3% |
Unknown | 12 | 41% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 28% |
Psychology | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Nursing and Health Professions | 1 | 3% |
Other | 3 | 10% |
Unknown | 13 | 45% |